Organigram GlobalSTU:0OG +0.23%61 Days Payable is 150.31 as of Mar. 2026, which is 4% above its 10-year median of 145.09. GuruFocus rates STU:0OG with a GF Score™ of 61/100 and a GF Value™ of €1.47 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 920 Drug Manufacturers companies, Organigram Global ranks better than 77.72% on this metric.
The historical rank and industry rank for Organigram Global's Days Payable or its related term are showing as below:
STU:0OG'
s Days Payable Range Over the Past 10 Years
Min: 61.82 Med: 145.09 Max: 802.19
Current: 159.78
During the past 13 years, Organigram Global's highest Days Payable was 802.19. The lowest was 61.82. And the median was 145.09.
STU:0OG's Days Payable is ranked better than 77.72% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs STU:0OG: 159.78
Organigram Global's Days Payable
increased
from Mar. 2025 (124.64) to Mar. 2026 (150.31).
It may suggest that Organigram Globaldelayed paying its suppliers.
Organigram Global Days Payable Related Terms
Organigram Global Days Payable Historical Data
* Premium members only.
The historical data trend for Organigram Global's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Organigram Global's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organigram Global Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organigram Global's Days Payable distribution charts can be found below:
* The bar in red indicates where Organigram Global's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Organigram Global's Days Payable for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organigram Global (STU:0OG) has a Days Payable of 150.31 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Organigram Global and its competitors. This is near median its historical median of 145.09. Over the past decade, Organigram Global's Days Payable has ranged from 61.82 to 802.19. According to the industry distribution chart, Organigram Global ranks #205 out of 920 companies in the Drug Manufacturers industry, placing it in the top 22.3%.
Is Organigram Global's Days Payable too high?
Organigram Global's current Days Payable of 150.31 is near median its 10-year median of 145.09. Over the past 10 years, this metric has ranged from a low of 61.82 to a high of 802.19. The Drug Manufacturers industry median Days Payable is 90.84. Organigram Global's value of 150.31 is 65.5% above this industry median. Based on the distribution chart, Organigram Global ranks #205 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Organigram Global has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organigram Global's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Organigram Global ranks #205 out of 920 companies for Days Payable. This places Organigram Global in the top 22% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. Organigram Global's value of 150.31 is 65.5% above this benchmark. Historically, Organigram Global's own Days Payable has ranged from 61.82 to 802.19 over the past decade. While the company's 10-year median is 145.09 vs. the industry median of 90.84, Organigram Global has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organigram Global's current Days Payable of 150.31 is 65.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Organigram Global and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organigram Global's current Days Payable is 150.31, which is near median its own 10-year median of 145.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organigram Global stock overvalued right now?
Based on GuruFocus' analysis, Organigram Global (STU:0OG) is currently considered Possible Value Trap. The stock's GF Value™ is €1.47, compared to a current price of €0.88 — trading 40.1% below its estimated fair value. The current Days Payable is 150.31, which is near median its 10-year median of 145.09 and 65.5% above the Drug Manufacturers industry median of 90.84. Organigram Global's overall GF Score™ is 61/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Organigram Global (STU:0OG), the current Days Payable is 150.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organigram Global (STU:0OG) Overvalued in 2026?
Based on GuruFocus' analysis, Organigram Global stock appears to be undervalued.
The current stock price of €0.88 is trading 40.1% below its estimated GF Value™ of €1.47.
GuruFocus considers Organigram Global to be Possible Value Trap.
Key valuation signals for STU:0OG:
Days Payable: 150.31 (near median its 10-year median of 145.09)
GF Value™: €1.47 vs. price of €0.88 (40.1% below fair value)
Industry Position: 65.5% above the Drug Manufacturers median (#205 of 920)
No single metric tells the full story. See the STU:0OG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
61GF Score
Get the complete analysis for STU:0OG
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0OG has been successfully added to your 
